ES2074490T3 - Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa. - Google Patents

Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.

Info

Publication number
ES2074490T3
ES2074490T3 ES90105405T ES90105405T ES2074490T3 ES 2074490 T3 ES2074490 T3 ES 2074490T3 ES 90105405 T ES90105405 T ES 90105405T ES 90105405 T ES90105405 T ES 90105405T ES 2074490 T3 ES2074490 T3 ES 2074490T3
Authority
ES
Spain
Prior art keywords
preparation
procedure
via intravenous
immunoglobin
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90105405T
Other languages
English (en)
Other versions
ES2074490T5 (es
Inventor
Norbert Dr Dipl-Chem Kothe
Dieter Dr Dipl-Chem Rudnick
Detlef Dr Dipl-Chem Piechaczek
Herwald Dr Klein
Detlef Dr Dipl-Biol Rohm
Michael Dr Dipl-Chem Kloft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotest Pharma GmbH
Original Assignee
Biotest Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8203787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2074490(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotest Pharma GmbH filed Critical Biotest Pharma GmbH
Publication of ES2074490T3 publication Critical patent/ES2074490T3/es
Application granted granted Critical
Publication of ES2074490T5 publication Critical patent/ES2074490T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

METODO Y ELABORACION DE UN PREPARADO G, QUE SOPORTA LA INMUNOGLOBINA INTRAVENENOSA, EL CUAL ESTA LIBRE DE GRUPOS, SUSTANCIAS VASOACTIVAS Y ENCIMAS PROTEOLITICAS Y ES APROPIADO PARA UN COLECTIVO DE PACIENTES, CONCRETAMENTE PARA LOS PACIENTES "INMUNOSUPRIMIDOS", QUE CONSTA DE UN MATERIAL DE SALIDA CON UN CONTENIDO G DE INMUNOGLOBINA, LIBRE DE FACTORES DE COAGULACION, CON UN TRATAMIENTO DE UN % DE VOLUMEN DE 0,4 A 1,5 DE ACIDOS DE OCTANO Y/O CON UNA CROMATOGRAFIA SIGUIENTE, ESPECIALMENTE, EN EL INTERCAMBIO DE CATIONES O ANIONES O DE UNA MATRIX DE CROMATOGRAFIA DE HIDROFOBEN.
ES90105405T 1990-03-22 1990-03-22 Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa. Expired - Lifetime ES2074490T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90105405A EP0447585B2 (de) 1990-03-22 1990-03-22 Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates

Publications (2)

Publication Number Publication Date
ES2074490T3 true ES2074490T3 (es) 1995-09-16
ES2074490T5 ES2074490T5 (es) 2004-02-16

Family

ID=8203787

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90105405T Expired - Lifetime ES2074490T5 (es) 1990-03-22 1990-03-22 Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.

Country Status (7)

Country Link
US (1) US5164487A (es)
EP (1) EP0447585B2 (es)
JP (1) JPH06107561A (es)
AT (1) ATE122054T1 (es)
DE (1) DE59009020D1 (es)
DK (1) DK0447585T4 (es)
ES (1) ES2074490T5 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
DK2272870T3 (da) * 1998-06-09 2013-08-05 Csl Behring Ag Fremgangsmåde til fremstilling af immunoglobuliner med henblik på intravenøs indgivelse og andre immunoglobulin-lignende produkter.
DE19904407C2 (de) * 1999-02-04 2001-09-20 Bayer Ag Vorrichtung zum Wechseln einer Düsenplatte eines Prillturmes und Verfahren zum automatisierten Wechsel
SE0001128D0 (sv) * 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
US20050272917A1 (en) * 2004-05-14 2005-12-08 Hematech, Llc Methods for immunoglobulin purification
TWI320788B (en) * 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
FR2895263B1 (fr) 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
CA2666607C (en) * 2006-11-01 2015-02-10 Biogen Idec Ma Inc. Method of isolating biomacromolecules using low ph and divalent cations
RU2009148891A (ru) 2007-06-01 2011-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Очистка иммуноглобулина
PT2271382E (pt) 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
JP5631301B2 (ja) * 2008-04-16 2014-11-26 バイオジェン・アイデック・エムエイ・インコーポレイテッド ポリアルキレングリコールおよび遷移金属を用いて生体高分子を単離する方法
CA2788863C (en) 2010-02-04 2020-07-07 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
FR2974301B1 (fr) * 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
SG11201505192RA (en) * 2013-02-28 2015-08-28 Agency Science Tech & Res Chromatographic purification of antibodies from chromatin-deficient cell culture harvests
KR20150122650A (ko) * 2013-02-28 2015-11-02 에이전시 포 사이언스, 테크놀로지 앤드 리서치 상승된 전도도에서 비이온성 유기 폴리머들의 존재에서의 단백질 정제
JP6474798B2 (ja) 2013-07-01 2019-02-27 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 方法
KR102356757B1 (ko) 2013-10-18 2022-02-03 노바셉 이큅먼트 솔루션즈 단백질 정제
EP4147761A1 (en) 2014-04-30 2023-03-15 Novo Nordisk A/S Methods for the purification of proteins using caprylic acid
MX388043B (es) 2014-12-03 2025-03-19 Csl Behring Ag Producto farmacéutico con estabilidad incrementada que comprende inmunoglobulinas.
KR101657690B1 (ko) * 2015-06-05 2016-09-19 주식회사 녹십자홀딩스 혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법
EP3275897A1 (en) 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
DE3640513A1 (de) * 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
EP0338229B1 (de) * 1988-04-19 1993-06-16 Biotest Pharma Gmbh Präparat mit Antikörperaktivität und breitem Wirkungsspektrum, daraus bestehende oder diese enthaltende Mittel und deren Verwendung zur Behandlung von bakteriell oder toxin-bedingten Erkrankungen und zur Bekämpfung von Protozoen
FR2632308B1 (fr) * 1988-06-07 1991-08-16 Fondation Nale Transfusion San Procede et installation de fractionnement en continu de proteines vegetales animales ou humaines
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process

Also Published As

Publication number Publication date
ES2074490T5 (es) 2004-02-16
ATE122054T1 (de) 1995-05-15
DK0447585T4 (da) 2003-09-01
EP0447585B1 (de) 1995-05-03
DK0447585T3 (da) 1995-05-29
DE59009020D1 (de) 1995-06-08
JPH06107561A (ja) 1994-04-19
US5164487A (en) 1992-11-17
EP0447585B2 (de) 2003-05-07
EP0447585A1 (de) 1991-09-25

Similar Documents

Publication Publication Date Title
ES2074490T3 (es) Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.
SE8504967D0 (sv) A pharmaceutical composition and a method of treating the body
DE19375061I2 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
ATE110578T1 (de) Von hydrogel angetriebene verabreichungsvorrichtung.
ATE157251T1 (de) Verwendung von inositoltriphosphat zur behandlung von entzündungen
KR900701261A (ko) 비만증 치료방법
DE3587941D1 (de) Gerät zur vorläufigen reperfusionsbehandlung von herzanfallsymptomen.
ES2187659T3 (es) Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.
DK0457849T3 (da) Klæbemiddel til elektrotransport
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
KR890700026A (ko) 건선 치료에 있어서 주석 프로토포르피린 및 주석 메조포르피린의 용도
ES2067624T3 (es) Un procedimiento de preparacion de una composicion farmaceutica liquida para administracion nasal.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
BR9201718A (pt) Concentrado de fator xi da coagulacao sanguinea de alta atividade especifica,apropriado para uso terapeutico e seu processo de preparacao
GB8727099D0 (en) Compositions containing melantonin/homologues
MX9203374A (es) Composicion farmaceutica que contiene l-alfa-glicerofosforilcolina.
PT95212A (pt) Processo para a preparacao de uma composicao para uso topico para o tratamento da fragilidade capilar, contendo defibrotide
ES2055761T3 (es) Procedimiento para la concentracion de los factores de coagulacion de la sangre ii, vii, ix y x.
DK0514367T3 (da) Lægemiddel indeholdende protein C
DE69115687D1 (de) Verwendung von spezifischen Fettsäuren zur Herstellung eines Medikaments zur Verabreichung durch Iontophorese
IL101675A (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
ATE244011T1 (de) Unterdrückung der thromboxanspiegel durch perkutane verabreichung von aspirin
ES2052670T3 (es) Utilizacion de derivados de 2-pirimidinil-1-piperazina.
AU2525488A (en) Use of metalloporphyrins to reverse the toxic effect of tumor therapy

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 447585

Country of ref document: ES